These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 462918)

  • 21. The effect of storage of whole blood on the association of factor VIII-related antigen and factor VIII-coagulant antigen.
    Hellings JA; Over J; van Mourik JA
    Scand J Haematol; 1982 Nov; 29(5):353-62. PubMed ID: 6818685
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Disparity between one- and two-stage factor VIII assays in measuring VIIIC in heparinized plasma.
    Rock G; Palmer DS
    Thromb Haemost; 1985 Dec; 54(4):780-3. PubMed ID: 3937275
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preservation of coagulation factors V and VIII during collection and subsequent storage of bank blood in ACD-A and CPD solutions.
    Weisert O; Jeremic M
    Vox Sang; 1973 Feb; 24(2):126-33. PubMed ID: 4682805
    [No Abstract]   [Full Text] [Related]  

  • 24. Use of plasma with high levels of ionised calcium in the production of model scale coagulation factor concentrates.
    Farrugia A; Douglas S; James J; Whyte G; Herrington R
    Thromb Haemost; 1990 Nov; 64(3):374-8. PubMed ID: 2128967
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stability of blood coagulation factors and inhibitors in blood drawn into half-strength citrate anticoagulant.
    Suontaka AM; Akerblom O; Blombäck M; Eriksson L; Högman CF; Payrat JM
    Vox Sang; 1996; 71(2):97-102. PubMed ID: 8873419
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of Na3-citrate on the solubility of cryoprecipitate (citrate effect on cryoprecipitate).
    Faludi E; Harsányi V
    Haematologia (Budap); 1981; 14(2):207-14. PubMed ID: 6792005
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A protocol for cryoprecipitate production.
    Burka ER; Harker LA; Kasper CK; Kevy SV; Ness PM
    Transfusion; 1975; 15(4):307-11. PubMed ID: 1166503
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A clinical trial of red-cell concentrate prepared from blood collected in half-strength citrate anticoagulant.
    Murphy WG; Palmer JB; Wilson R; Prowse CV; McClelland DB
    Transfus Med; 1991 Mar; 1(1):25-9. PubMed ID: 9259823
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The assay of factor VIII: C in heparinized plasma: a polybrene neutralization method.
    Cumming AM; Wensley RT; Delamore IW
    Thromb Haemost; 1986 Feb; 55(1):58-60. PubMed ID: 3085265
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhanced yield of antihemophilic factor and von Willebrand factor by cryoprecipitation with polyethylene glycol.
    Johnson AJ; Macdonald VE; Brind J
    Vox Sang; 1979; 36(2):72-6. PubMed ID: 313629
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factor VIII collection by pheresis.
    McLeod BC; Sassetti RJ; Cole ER; Pierce MI
    Lancet; 1980 Sep; 2(8196):671-3. PubMed ID: 6106786
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Determinants of factor VIII recovery in cryoprecipitate.
    Kasper CK; Myhre BA; McDonald JD; Nakasako Y; Feinstein DI
    Transfusion; 1975; 15(4):312-22. PubMed ID: 1166504
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of factor VIII-rich cryoprecipitate and the plasma fibronectin-rich, heparin-precipitable fraction prepared from single-donor plasma units.
    Menitove JE; Amrani DL; Meh D; Frenzke M; Mosesson MW
    Transfusion; 1987; 27(6):491-5. PubMed ID: 3500532
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preparation of stable intermediate-purity factor VIII concentrate with a note on high-purity factor VIII.
    Margolis J; Rhoades P
    Vox Sang; 1979; 36(6):369-74. PubMed ID: 494575
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An improved thaw-siphon method for the cryoprecipitate preparation.
    Kang EP
    Vox Sang; 1980; 38(3):172-7. PubMed ID: 6770544
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of delayed blood processing on the yield of factor VIII in cryoprecipitate and factor VIII concentrate.
    Hughes C; Thomas KB; Schiff P; Herrington RW; Polacsek EE; McGrath KM
    Transfusion; 1988; 28(6):566-70. PubMed ID: 3143170
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Factors that influence the process of 51chromium labeling of human granulocytes isolated from blood by counterflow centrifugation.
    Kurtz SR; Carciero R; Valeri CR
    Transfusion; 1979; 19(4):398-403. PubMed ID: 473342
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The influence of donor characteristics and preparation methods on the potency of human cryoprecipitate.
    Burka ER; Puffer T; Martinez J
    Transfusion; 1975; 15(4):323-8. PubMed ID: 1166505
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stability of red cell antigens and plasma coagulation factors stored in new formulation plastic blood containers.
    Snyder EL; Hezzey A; Weirich F; Mosher DF; Davisson W; Buchholz DH
    Transfusion; 1983; 23(1):49-53. PubMed ID: 6829059
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Development and characterization of a high-purity human factor VIII concentrate submitted to 2 specific virus inactivation treatments (FANDHI)].
    Ristol P; Gensana M; Fernández J; Massot M; Bhattacharya P; Jorquera JI
    Sangre (Barc); 1996 Apr; 41(2):125-30. PubMed ID: 9045352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.